Literature DB >> 22177211

Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility.

Antonio S Salinas-Sánchez1, María J Donate-Moreno, María-Pilar López-Garrido, José M Giménez-Bachs, Julio Escribano.   

Abstract

PURPOSE: CYP1B1 activates procarcinogens in some human tissues, including the urinary tract. Changes related to genetic polymorphisms are a known risk factor for cancer. We analyzed the association between CYP1B1 sequence variations and bladder cancer.
MATERIALS AND METHODS: Sequence variations in the coding region (exons 2 and 3) and the neighboring introns of CYP1B1 were analyzed by direct polymerase chain reaction and DNA sequencing in 208 unrelated patients with bladder cancer and 208 healthy controls.
RESULTS: We identified 6 known single nucleotide polymorphisms organized into 2 linkage disequilibrium blocks. The Ala/Ala and Leu/Val genotypes of the Ala119Ser and Leu432Val polymorphisms were significantly more common in patients than in controls (55.3% vs 42.8% and 54.8% vs 42.3%, respectively). The strongest individual single nucleotide polymorphism risk was found under an over dominant model for Leu432Val (OR 1.65, CI 95% 1.12-2.44). The 2 susceptibility single nucleotide polymorphisms were predicted to be structured into 4 haplotypes and more than 10 diplotypes. No individual haplotype was associated with bladder cancer but the diplotype Ala-Leu/Ala-Val was significantly overrepresented in cases compared to controls (31.73% vs 17.31%, OR 2.22, 95% CI 1.36-3.62, p = 0.001). The OR was approximately 1.6 for the individual genotypes Ala/Ala and Leu/Val, which increased to 2.2 for the Ala-Leu/Ala-Val diplotype. A risk occupation had a modifying effect, increasing the crude OR of the combined genotype Ala/Ala + Leu/Val from 2.2 to 8.3.
CONCLUSIONS: This study provides strong evidence for the role of common CYP1B1 variants as risk factors for bladder cancer, which increases with occupational exposure.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177211     DOI: 10.1016/j.juro.2011.10.063

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.

Authors:  V Le Morvan; S Litière; A Laroche-Clary; S Ait-Ouferoukh; R Bellott; C Messina; D Cameron; H Bonnefoi; J Robert
Journal:  Pharmacogenomics J       Date:  2014-06-24       Impact factor: 3.550

2.  The CYP1B1 Leu432Val polymorphism and risk of urinary system cancers.

Authors:  Yi Liu; Chang-sheng Lin; Ai-min Zhang; Hua Song; Chang-chun Fan
Journal:  Tumour Biol       Date:  2014-01-23

3.  Cytochrome P450 1B1 polymorphisms and risk of renal cell carcinoma in men.

Authors:  Inik Chang; Shinichiro Fukuhara; Darryn K Wong; Ankurpreet Gill; Yozo Mitsui; Shahana Majid; Sharanjot Saini; Soichiro Yamamura; Takeshi Chiyomaru; Hiroshi Hirata; Koji Ueno; Sumit Arora; Varahram Shahryari; Guoren Deng; Z Laura Tabatabai; Kirsten L Greene; Dong Min Shin; Hideki Enokida; Hiroaki Shiina; Norio Nonomura; Rajvir Dahiya; Yuichiro Tanaka
Journal:  Tumour Biol       Date:  2014-07-17

4.  Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jie-Ying Liu; Yu Yang; Zhi-Zhong Liu; Jian-Jun Xie; Ya-Ping Du; Wei Wang
Journal:  Mol Genet Genomics       Date:  2014-12-05       Impact factor: 3.291

5.  Genetic polymorphisms in the CYP1A1 and CYP1B1 genes and susceptibility to bladder cancer: a meta-analysis.

Authors:  Yan-Zhi Chen; Jing Li; Yu-Xia Zhao; Dan Liu; He-Tong Wang; Ya Gao; Ying Chen
Journal:  Mol Biol Rep       Date:  2014-04-10       Impact factor: 2.316

Review 6.  Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.

Authors:  Gera Narendra; Shalki Choudhary; Baddipadige Raju; Himanshu Verma; Om Silakari
Journal:  Clin Pharmacokinet       Date:  2022-09-30       Impact factor: 5.577

7.  ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.

Authors:  Aurélie Dumont; Diane Pannier; Agnès Ducoulombier; Emmanuelle Tresch; Jinying Chen; Andrew Kramar; Françoise Révillion; Jean-Philippe Peyrat; Jacques Bonneterre
Journal:  Springerplus       Date:  2015-07-07

Review 8.  Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis.

Authors:  Weifan Jiang; Guang Sun; Jianhua Xiong; Xiaoqing Xi; Zimin Shi
Journal:  Diagn Pathol       Date:  2014-06-09       Impact factor: 2.644

9.  Bladder cancer: a simple model becomes complex.

Authors:  Giovanni Battista Di Pierro; Caterina Gulia; Cristiano Cristini; Giorgio Fraietta; Lorenzo Marini; Pietro Grande; Vincenzo Gentile; Roberto Piergentili
Journal:  Curr Genomics       Date:  2012-08       Impact factor: 2.236

10.  Genetic polymorphism intermingled with environmental factors substantially contributes to the bladder cancer progression.

Authors:  Stanisław Wroński
Journal:  Cent European J Urol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.